June 24 (Reuters) - Veru Inc VERU.O:
VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION
VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION
VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION
VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS
VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM
VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM
Source text: ID:nGNXbbvp7V
Further company coverage: VERU.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.